Tumor necrosis factor and the acute metabolic response to tissue injury in man
- PMID: 3139712
- PMCID: PMC442686
- DOI: 10.1172/JCI113733
Tumor necrosis factor and the acute metabolic response to tissue injury in man
Abstract
Tumor necrosis factor (cachectin), a protein produced by monocytes and macrophages, has been implicated as an important mediator of the lethal effects of endotoxic shock and the cachexia of chronic infection. Recombinant human tumor necrosis factor alpha (rTNF) was given intravenously to patients as part of an antineoplastic trial. Fever, tachycardia, and at higher doses, hypotension occurred after a single injection of rTNF. Metabolic effects after rTNF administration were dose related and included enhanced energy expenditure with elevated CO2 production, increased whole body protein metabolism and peripheral amino acid efflux from the forearm, and decreased total arterial amino acid levels associated with a significant increase in plasma cortisol. Elevated serum triglycerides, as well as increased glycerol and free fatty acid turnover were seen, suggesting increased whole body lipolysis and fat utilization after rTNF. These findings indicate that administration of TNF in man reproduces many of the acute physiologic and metabolic responses to tissue injury, including energy substrate mobilization.
Similar articles
-
IL-6/IFN-beta-2 as a circulating hormone. Induction by cytokine administration in humans.J Immunol. 1989 Mar 1;142(5):1542-7. J Immunol. 1989. PMID: 2783945
-
Tumor necrosis factor and endotoxin induce similar metabolic responses in human beings.Surgery. 1988 Aug;104(2):280-6. Surgery. 1988. PMID: 2456628
-
High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma.J Clin Oncol. 1992 Jan;10(1):52-60. doi: 10.1200/JCO.1992.10.1.52. J Clin Oncol. 1992. PMID: 1727926 Clinical Trial.
-
Recombinant human TNF-alpha: preclinical studies and results from early clinical trials.Immunol Ser. 1992;56:567-87. Immunol Ser. 1992. PMID: 1550875 Review.
-
[Similarity and synergy of trauma and sepsis: role of tumor necrosis factor-alpha and interleukin-6].Acta Anaesthesiol Sin. 1996 Sep;34(3):141-9. Acta Anaesthesiol Sin. 1996. PMID: 9084538 Review. Chinese.
Cited by
-
Metabolic effects of cachectin/tumor necrosis factor are modified by site of production. Cachectin/tumor necrosis factor-secreting tumor in skeletal muscle induces chronic cachexia, while implantation in brain induces predominantly acute anorexia.J Clin Invest. 1990 Dec;86(6):2014-24. doi: 10.1172/JCI114937. J Clin Invest. 1990. PMID: 2254457 Free PMC article.
-
Perturbations of triglycerides but not of cholesterol metabolism are prevented by anti-tumour necrosis factor treatment in rats bearing an ascites hepatoma (Yoshida AH-130).Br J Cancer. 1995 Nov;72(5):1138-43. doi: 10.1038/bjc.1995.477. Br J Cancer. 1995. PMID: 7577459 Free PMC article.
-
Acute treatment with tumour necrosis factor-alpha induces changes in protein metabolism in rat skeletal muscle.Mol Cell Biochem. 1993 Aug 11;125(1):11-8. doi: 10.1007/BF00926829. Mol Cell Biochem. 1993. PMID: 8264567
-
IL-6-like cytokines and cancer cachexia: consequences of chronic inflammation.Immunol Res. 2001;23(1):41-58. doi: 10.1385/IR:23:1:41. Immunol Res. 2001. PMID: 11417859 Review.
-
Xanthine oxidase inhibitor urate-lowering therapy titration to target decreases serum free fatty acids in gout and suppresses lipolysis by adipocytes.Arthritis Res Ther. 2022 Jul 25;24(1):175. doi: 10.1186/s13075-022-02852-4. Arthritis Res Ther. 2022. PMID: 35879786 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources